Expediting the Diagnosis of Heart Attack with Atellica VTLi Patient-Side Analyzer for Industry First Fingerstick High-Sensitivity Troponin I at Point-of-Care

Siemens HealthineersSiemens Healthineers announced today the company's Atellica VTLi Patient-Side Immunoassay Analyzer(1) has obtained CE mark and is expected to be available later this spring. The Atellica VTLi analyzer provides lab standard, high-sensitivity cardiac troponin I (hs-cTnI) test results to clinicians in eight minutes using a patient's fingerstick blood sample. With this industry first technology, Siemens Healthineers is helping to improve the patient care paradigm with its disruptive technology, providing hs-cTnI results at the patient's side to help clinicians properly diagnose and treat heart attacks with confidence.

"Siemens Healthineers is among the best-in-class with cardiac disease state solutions, immunoassays, and critical care diagnostics. Now we are raising the bar as the first company to offer a true point-of-care high-sensitivity cardiac troponin I test with results comparable to laboratory performance using just a fingerstick sample. Healthcare providers have been waiting decades for hs-cTnI at the point of care and now the wait is over. This new technology further expands Siemens Healthineers' broad cardiac portfolio throughout the entire patient care continuum," said Christoph Pedain, PhD, Head of Point of Care Diagnostics, Siemens Healthineers.

Globally, millions of patients present annually to the emergency room with symptoms that may be related to a heart attack. Responsible for an estimated 31 percent of all deaths worldwide, cardiovascular disease is the leading cause of death.(2) Fast triage for patients presenting with symptoms can help save lives. Clinicians primarily rely on the central laboratory for critical blood test results before they can make care decisions for their patients. This process can take an hour or more to get results. The substantial reduction in turnaround time achieved when introducing the wireless, handheld Atellica VTLi analyzer may offer clinicians a fast pathway to help diagnose and treat their patients, helping to accelerate care, improve patient outcomes, and reduce the strain felt in overcrowded EDs.

When a patient presents at the hospital with symptoms of a potential heart attack, securing favorable outcomes depends on the speedy availability of test results, and the confidence care providers have in them. "In today's busy emergency departments across the globe, there is a demand by clinicians for the rapid measurement of cardiac troponin, using guideline-recommended, high-sensitivity assays, to quickly and accurately rule in and rule out myocardial injury and myocardial infarction in patients presenting with symptoms suggestive of ischemia," said Dr. Fred Apple, PhD, Medical Director of clinical laboratories, clinical chemistry, point-of-care testing, and clinical and forensic toxicology laboratories at Hennepin County Medical Center. "The Siemens Healthineers Atellica VTLi point-of-care assay technology, utilizing whole blood with result turn-around times in as fast as eight minutes, provides a high-sensitivity cardiac troponin I measurement that is equivalent to the diagnostic and analytical accuracy of instruments found in the central laboratory. I believe this POC system could easily integrate into existing hospital and clinic workflows, with the potential to impact patient care and clinical outcomes, with operational and financial efficiencies."

The Atellica VTLi system has wireless capability that easily integrates and directly connects to data management systems, including the Siemens Healthineers POC Ecosystem Solution, and the laboratory and hospital information systems. Together, this offering provides the laboratory centralized control over decentralized point-of-care testing.

The Atellica VTLi immunoassay analyzer is the resulting innovation stemming from Siemens Healthineers' acquisition of Minicare BV, which was completed on July 2, 2019.

About Siemens Healthineers

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalising healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers, which has approximately 54,000 employees worldwide, generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion.

1. The products/features (mentioned herein) are not commercially available in all countries. Not available for sale in the U.S.A. Their future availability cannot be guaranteed.
2. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

Most Popular Now

Oracle Buys Cerner

Oracle Corporation (NYSE: ORCL) and Cerner Corporation jointly announced an agreement for Oracle to acquire Cerner through an all-cash tender offer for $95.00 per share, or approximately $28.3 billion in...

Philips and IJsselland Hospital Sign Lon…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has signed a 12-year strategic partnership with IJsselland Hospital (Capelle aan den Ijssel, The Netherlands)...

Computer Programs and Mobile Apps may He…

The COVID-19 pandemic has had a major impact on mental health across the globe. Depression is predicted to be the leading cause of lost life years due to illness by...

AI Points the Way to Better Doctor-Patie…

A computer analysis of hundreds of thousands of secure email messages between doctors and patients found that most doctors use language that is too complex for their patients to understand...

Could EKGs Help Doctors use AI to Detect…

Pulmonary embolisms are dangerous, lung-clogging blot clots. In a pilot study, scientists at the Icahn School of Medicine at Mount Sinai showed for the first time that artificial intelligence (AI)...

Mayo Clinic Researchers Use AI, Biomarke…

Treatment options for rheumatoid arthritis have often relied on trial and error. Now Mayo Clinic researchers are exploring the use of artificial intelligence (AI) and pharmacogenomics to predict how patients...

Open Call DIGITAL-2021-DEPLOY-01-TWINS-H…

The development of digital twins in healthcare (DTH) has progressed substantially, profiting from advances in science and technology. In order to exploit their benefits in view of better prevention approaches...

Computer Model of Blood Enzyme

Membrane-associated proteins play a vital role in a variety of cellular processes, yet little is known about the membrane-association mechanism. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is one such protein with an...

Mjog by Livi Launches Remote Monitoring …

Mjog by Livi has launched a remote monitoring tool that will help GPs support and monitor people with depression through messages sent to their smartphones. The latest data from the Office...

4.5 Million Euros in EU Funding for Saar…

This year, three computer scientists from Saarbrücken were awarded an "ERC Starting Grant" by the European Research Council. This award, endowed with 1.5 million euros each, is among the most...

2022 EU4Health Work Programme Adopted to…

Today the Commission has adopted the second EU4Health work programme. In 2022, the EU4Health will continue to invest in building stronger, more resilient health systems and pave the way for...

Five NHS Trusts in Surrey and Sussex to …

A consortium of NHS trusts that covers a population of circa 1.2 million will gain immediate access to important patient imaging, and will mobilise a regional workforce for patients, following...